Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "into the final PK / PD model, ", where dexamethasone ( DEX ) exerted dexamethasone ( DEX ) s antitumor efficacy by inhibiting the proliferation of tumor cells", enhanced dexamethasone ( DEX ) responses by decreasing the sensitivity parameter EC(50 )" provenance.
- OBJECT label "the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "the death rate in The coronavirus disease 2019 ( COVID)-19 ) patients" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "significantly, in 2020, in comparison to 2019 ( p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections )" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.
- OBJECT label "the effect of the ensuing cytokine storm in critically ill patients COVID-19" provenance.